Implication of G Protein-Coupled Receptor 43 in Intestinal Inflammation: A Mini-Review

Guan Yang¹, Siyuan Chen¹, Baichuan Deng¹, Chengquan Tan¹, Jinping Deng¹*, Guoqiang Zhu², Yulong Yin¹ and Wenkai Ren¹,²*

¹Guangdong Provincial Key Laboratory of Animal Nutrition Control, Subtropical Institute of Animal Nutrition and Feed, College of Animal Science, South China Agricultural University, Guangzhou, Guangdong, China. ²Jiangsu Co-Innovation Center for Important Animal Infectious Diseases and Zoonoses, Joint International Research Laboratory of Agriculture and Agri-Product Safety of Ministry of Education of China, College of Veterinary Medicine, Yangzhou University, Yangzhou, China

Short chain fatty acids (SCFAs, e.g., acetate, propionate, and butyrate) are a subset of fatty acids that are produced by gut microbiota during the fermentation of dietary fiber. They modulate different processes in the gastrointestinal tract and play various positive roles in mediating the intestinal health. Most beneficial roles of SCFAs in the gastrointestinal tract are mediated by directly activating its receptor, G protein-coupled receptor 43 (GPR43, also known as FFAR2). Various recent studies have demonstrated the role of GPR43 in intestinal inflammatory diseases, such as inflammatory bowel diseases. These SCFAs-mediated regulations of intestinal health are associated with neutrophil chemotaxis, T cell differentiation, activation, and subsequent cytokines production. Therefore, GPR43 could potentially be a drug target for intestinal inflammatory diseases. In this review, we review the current knowledge on the regulatory mechanisms associated with GPR43 in intestinal inflammation. The role of GPR43-mediated regulation of antibody responses is also discussed.

Keywords: G protein-coupled receptor 43, inflammation, short chain fatty acids, inflammatory bowel diseases, intestinal microbiota

INTRODUCTION

Inflammatory bowel diseases (IBD) are chronic inflammatory diseases with unknown etiology. It comprises the chronic relapsing inflammatory disorders: Crohn’s disease and ulcerative colitis (1). Although the pathogenesis of IBD remains unknown, it is widely accepted that the pathogenesis of IBD involves immune and environmental factors, including intestinal inflammation and gut microbiota (1–6). Next Generation Sequencing and Genome-Wide Association Studies have revealed strong associations of polymorphisms in some gene loci with IBD (7). Recent evidence also showed the single amino acid change would directly affect the protein function and conformation, suggesting the possible role of single amino acid polymorphisms in genetic predisposing of IBD (8). Inflammation is a cascade of responses triggered by immune cells and cytokines to defend the body against injuries, harmful stimuli, infection, or microbial toxins (9). As the intestinal mucosa is in constant contact with a diverse array of exogenous microorganisms and substances, inflammatory responses are necessary for the maintenance of gastrointestinal homeostasis (1, 10). However, sustained and excessive inflammation responses in the intestinal mucosa are associated with various gastrointestinal pathologies, such as IBD (9, 11). Notably, numerous investigations have indicated that the homeostasis of the intestinal microbiota could positively influence intestinal immunity,
and protect against the development of intestinal inflammatory diseases, while intestinal dysbiosis leads to intestinal diseases (12, 13). For example, a feature of human IBD is a change in the number of “healthy” microbiota such as Bifidobacterium and Bacteroides (14). The mechanisms involved in these processes are not fully unraveled, but a group of molecules known to be involved in the cross talk between the microbiome and the gut immune system are short chain fatty acids (SCFAs). SCFAs refer to carboxylic acids with aliphatic tails of less than six carbons such as formic, acetic, propionic, butyric, isobutyric, valeric, isovaleric, and 2-methyl-butyric acids that are produced by gut microbiota during the fermentation of unabsorbed carbohydrates and dietary fiber. SCFAs are found in high concentrations in the intestinal tract, ranging from 70 to 140 mM in proximal colon and 20 to 70 mM in the distal colon, with acetate as the predominant SCFA (15). In addition to providing energy to gut epithelium and peripheral tissues, SCFAs also promote intestinal epithelial integrity and aid in the repair of wounded epithelium (16). They also involved in many physiological processes in humans and rodents by acting as signaling molecules. Intriguingly, various studies have demonstrated the beneficial effects of fermentable dietary fiber or SCFAs in the progression of colitis, reducing risks of cardiovascular disease, colon cancer, obesity, and diabetes (17–21). These SCFA-mediated regulations are achieved through the activation of G protein-coupled receptors (GPCRs), inhibition of histone deacetylase (HDAC), stimulation of histone acetyltransferase activity, and stabilization of the hypoxia-inducible factor (22–25). GPCRs can be classified into the category of moonlighting proteins (26–28) as they can carry out different types of functions. Details on the effects of SCFAs and GPCRs on IBD have been reviewed by others (29).

In this review, we summarize current knowledge on the regulatory mechanisms associated with G protein-coupled receptor 43 (GPR43)-mediated effects in intestinal inflammation.

THE SCFA RECEPTOR GPR43

The superfamily of GPCRs is one of the largest families of proteins in the mammalian genome and shares a conserved structure composed of seven transmembrane helices (30). SCFA-sensing GPCRs include GPR41 (FFAR3), GPR43 (FFAR2), GPR109, and olfactory factor 78, which are present in intestinal epithelial cells, adipocytes, and immune cells (31). Most notable among the SCFA targets is the GPR43, which is abundantly expressed in the intestines, adipose tissues, with the highest expression found in immune cells such as monocytes and neutrophils (32–35), suggesting the possible regulatory functions of GPR43 in the recruitment of these cell types during inflammatory responses in vivo. GPR43 has drawn much attention in recent years, and might be the mechanism through which SCFAs directly regulate the immune cells and the process of inflammatory diseases (36, 37). It could be activated by SCFAs, with acetate and propionate serve as the most potent activators followed by butyrate and other SCFAs (32, 33). Activation of GPR43 by acetate and propionate, in turn, induce both GoS, and Goq, which inhibits cAMP production but increases intracellular levels of calcium ions (32–34). Many studies have investigated the role of GPR43 in regulating intestinal inflammatory responses. GPR43-deficient mice have exacerbated disease symptoms in models of dextran sulfate sodium (DSS)-induced colitis as evidenced by reduced colon length, an increased disease activity index, severe inflammation, and increased myeloperoxidase (MPO) activity in the colon, and these symptoms could not be ameliorated by 150 mM (37) or 200 mM (36) of acetate treatment, although same doses of acetate treatment significantly improved the disease course of DSS-induced colitis in WT mice (36, 37). These results suggested that GPR43 mediates the protective effects of SCFA in intestinal inflammation. However, contradictory roles of GPR43 were reported. Sina et al. reported that GPR43-deficient mice have reduced tissue damage and inflammatory cell infiltration in acute DSS colitis (4% DSS in water for 6 days) (38). GPR43-deficient mice were even found to be protected from chronic colitis (e.g., reduced MPO, increased colon length) induced by three cycles of 2% DSS administration (one cycle: 5 days 2% DSS in drinking and 5 days regular water) (38). A possible explanation for the different outcomes for these studies may be due to differences in the mice. As Maslowski et al. (36) and Masui et al. (37) used mice provided by Deltagen, whereas those used by Sina et al. (38) were made by Lexicon Pharmaceuticals. In addition, Kespohl et al. found that 100 mM sodium butyrate treatment for 3 weeks exacerbated disease severity in 1.5% DSS model of germ free mice possibly through inducing the expression of T-bet and IFN-γ in a GPR43-independent manner (39). A recent study in comparing the effects of SCFA and GPR43 agonists on intestinal barrier function found that SCFA could enhance the intestinal barrier function and inhibit the immune cell activation but in a GPR43-independent pathway (16). Furthermore, although GPR43 plays positive roles in mounting the acute inflammatory responses after 2,4,6-trinitrobenzene sulfonic acid (TNBS) treatment, reduced acute immune responses in the GPR43-deficient mice results in the delayed clearance of pathogens at early time points (40). Taken together, these results indicate the importance of GPR43 in regulating gut immunity as well as in linking diet, gut microflora, and the body’s inflammatory responses. These results also suggest different interpretations of experimental outcomes are likely and largely dependent on the experimental models and time points chosen for analysis.

GPR43 AND NEUTROPHIL CHEMOTAXIS

Polymorphonuclear leukocytes (PMNs; neutrophils) are the most abundant form of white blood cells, comprising approximately 60% of all white blood cells during non-infectious states in humans. It is well known that neutrophils play a key role in the battle against invading pathogens by delivering the anti-microbial molecules and reactive oxygen intermediates (41). In addition, neutrophils also help to regulate other immune responses by generating signals that recruit monocytes and dendritic cells, and help to determine macrophage polarization (42). Thus, efficient trafficking of neutrophils to the infected sites in the body is critical for host defense against pathogenic challenge. The key pathological feature of both human and experimental colitis models is the significant migration of PMNs into the lamina
propria and epithelial layer (43, 44), which could be regulated by many factors such as the presence of various chemokines and upregulation of integrins (45, 46). Among all these factors that regulate the migration of PMNs, SCFAs–GPR43 axis attracted a lot of interest.

Previous study has demonstrated the role of sodium acetate and sodium propionate in inducing the chemotaxis of human PMNs with a bell-shaped dose–response curve with an optimal concentration of 1 mM (33). In rodents, SCFAs could stimulate the neutrophil migration, which is associated with an increased production of the chemotactic cytokine CINC-2αβ and the increased expression of L-selectin on the neutrophil surface (47). In addition, SCFAs induced activation of GPR43 is implicated in directional migration of neutrophils in vitro. GPR43-dependent signaling is able to phosphorylate p38 mitogen-activated protein kinase (MAPK) and activate MAPK pathway, which has been considered as a major determinant contributor to chemotaxis in PMNs (48), indicating the important role of SCFA-induced GPR43-dependent signaling on neutrophil migration. In another in vitro study using bone marrow-derived neutrophils from wild-type and GPR43-deficient mouse, activation of the GPR43 in wild-type but not GPR43-deficient neutrophils support neutrophil motility and direction sensing, which allows neutrophils to efficiently migrate toward a source of acetate, propionate, or butyrate (49). Mechanistically, this GPR43-dependent chemotaxis requires PI3Kγ, Rac2, p38, and ERK (49).

GPR43-deficient mice develop exacerbated inflammation in models for colitis likely contributed to higher production of inflammatory mediators and increased neutrophil infiltration/activation (36). GPR43-deficient neutrophils showed increased chemotaxis toward bacterial products (fMLP) and to the complement fragment C5a (36) or the classic chemotactic receptor, CXCL1 (50). These data further confirm GPR43 as a chemotactic receptor for neutrophils. However, despite the fact that GPR43 regulating the recruitment of the neutrophils, its relevance with chemokine production and expression of adhesion molecules, which may be relevant to the effect of these fatty acids on leukocyte recruitment, is still not clear. The interaction of SCFA–GPR43 on neutrophils may play an immune modulation role at the intestinal level, inhibiting acute bacterial transmigration, but also an anti-inflammatory role in chronic inflammatory responses.

**GPR43 AND CYTOKINES EXPRESSION**

Naïve CD4+ T cells differentiate into a variety of subsets including T helper (Th)1, Th2, and Th17 cells as defined by their pattern of cytokine production and immune function (51, 52). Cytokines in the intestinal epithelium are important components initiated by the immune system for maintaining normal gut homeostasis. A disturbance of the cytokines profile in favor of inflammation may lead to the disease state, such as the observation in IBD. SCFAs can induce the generation of Tregs and affect Th1, Th2, and Th17 cell differentiation and activation [reviewed in Ref. (53)]. Studies have also shown that SCFAs modulate colitis by regulating inflammatory cytokines production in a GPR43-dependent pathway (37, 40). However, the roles of GPR43 in the production of inflammatory cytokines are controversial. Masui and colleagues showed that DSS-treated GPR43-deficient mice exhibited severer disease symptoms with higher IL-17 and TNF-α but similar IL-10 expression compared with wild-type mice (37). Treatment of wild-type mice with 150 mM acetate markedly improved the disease indexes associated with decreased IL-17 and TNF-α and increased IL-10 level, while no effects observed in GPR43-deficient mice in model of DSS-induced colitis (37). Blocking the GPR43 signaling by anti-GPR43 antibody also inhibited the effect of acetate suggesting this regulation of cytokine production is GPR43-dependent (37).

In a different colitis model induced by administration of ethanol or TNBS, Kim et al. found that GPR43-deficient mice showed reduced inflammatory responses and had slower immune responses against *Citrobacter rodentium* infection (40). Failure to clear *C. rodentium* at early time points was associated with low frequencies of Th1 and Th17 cells in the colon as well as delayed induction of inflammatory cytokines, IFN-γ, and chemokines (CXCL1 and CXCL2). The different roles of GPR43 in these two studies are likely caused by the different induction of colitis. DSS colitis switches from a Th1–Th17-mediated acute inflammation to a Th2-mediated inflammatory response as disease becomes chronic while TNBS colitis exhibits heightened Th1–Th17 response in the chronic state (54). In agreement with the results by Masui et al., they also found that GPR43 was required to recruit leukocytes and activate effector T cells in the intestine (40). Furthermore, the induced production of chemokines and cytokines were associated with the activation of ERK1/2 and p38 MAPK signaling pathways (40). In addition, a recent study demonstrated that acetate promotes T-cell differentiation into Th1 and Th17 cells (55). Interestingly, they found this effect of SCFAs on T cell differentiation is independent of GPR41 or GPR43, but dependent on direct HDAC inhibitor activity (55), suggesting that GPR43 may not be directly involved in SCFA regulation of naïve T cell differentiation. However, this result is in direct conflict with another study showing that SCFAs directly suppress HDACs in a GPR43-dependent manner (56). Butyrate also reduces surface expression of chemotactrant receptors C5aR and CXCR2 in neutrophils through GPR43 receptor (36). Hence, more research on the biology of GPR43 is required to confirm the role of GPR43 in regulating inflammation in different models.

**CONCLUDING REMARKS**

SCFA levels decreased remarkably in IBD patients compared with healthy individuals supporting the notion that SCFAs play an important role in the pathogenesis of IBD (57, 58). Administration of SCFAs or prebiotics that promote the SCFA production has long been used to treat IBD patients (59–63). In addition to their role in regulating intestinal T cell differentiation in gut mucosa, SCFAs can also affect the gut B cell development and antibody responses. Although there is a variety of evidence indicating that the GPR43 is involved in intestinal inflammation, whether GPR43 is a positive or negative modulator in intestinal inflammation remains controversial. This
controversial also apply to the SCFA’s regulation on B cells. Kim et al. reported that SCFAs promote plasma B cell differentiation by controlling the gene expression that is necessary for antibody production in an SCFA receptor-independent manner (64). However, Wu et al. showed that acetate promotes IgA production in an SCFA receptor-independent manner (65). Taken together, GPR43 participates in the regulation of intestinal inflammation may be associated with neutrophil recruitment and cytokine production (Figure 1). Future studies are expected to reveal the regulatory mechanisms associated with GPR43 in intestinal inflammation. The discovery of drugs acting on GPCRs has been extremely successful, thus GPR43 may also represent a promising therapeutic target for the treatment of intestinal diseases, such as IBD.

REFERENCES

1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature* (2011) 474(7351):298–306. doi:10.1038/nature10208
2. Ren W, Chen S, Yin J, Duan J, Li T, Liu G, et al. Dietary arginine supplementation of mice alters the microbial population and activates intestinal innate immunity. *J Nutr* (2014) 144(6):988–95. doi:10.3945/jn.114.192120
3. Ren W, Duan J, Yin J, Liu G, Cao Z, Xiong X, et al. Dietary L-glutamine supplementation modulates microbial community and activates innate immunity in the mouse intestine. *Amino Acids* (2014) 46(10):2403–13. doi:10.1007/s00726-014-1793-0
4. Ren W, Yin J, Wu M, Liu G, Yang G, Xiong X, et al. Serum amino acids profile and the beneficial effects of L-arginine or L-glutamine supplementation in dextran sulfate sodium colitis. *PLoS One* (2014) 9(6):e97815. doi:10.1371/journal.pone.0097815
5. Ruan Z, Liu S, Zhou Y, Mi S, Liu G, Wu X, et al. Chlorogenic acid decreases intestinal permeability and increases expression of intestinal tight junction proteins in weaned rats challenged with LPS. *PLoS One* (2014) 9(6):e97815. doi:10.1371/journal.pone.0097815
6. Tang Y, Tan B, Xiong X, Li F, Ren W, Kong X, et al. Methionine deficiency reduces autophagy and accelerates death in intestinal epithelial cells infected with enterotoxigenic *Escherichia coli*. *Amino Acids* (2014) 47(10):2199–204. doi:10.1007/s00726-014-1781-4
7. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. *Nat Genet* (2011) 43(11):1066–73. doi:10.1038/ng.952
8. Chen C, Jeffery C. Analysis of protein sequence and structural consequences of amino acid variants associated with autoimmune inflammatory bowel disease. *Biophys J* (2018) 114(3):189a. doi:10.1016/j.bpj.2017.11.1059
9. Romier B, Schneider YJ, Larondelle Y, During A. Dietary polyphenols can modulate the intestinal inflammatory response. *Nutr Rev* (2009) 67(7):363–78. doi:10.1111/j.1753-4887.2009.00210.x
10. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. *Nat Rev Microbiol* (2011) 9(5):356–68. doi:10.1038/nrmicro2546

AUTHOR CONTRIBUTIONS

GY and WR have designed the review article and approved the final manuscript. GY wrote the review article. BD and CT helped to find references. SC, JD, GZ, and YY revised the review article.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant Nos. 31790411), the National Key Research and Development Program of China (Grant Nos. 2018YFD0500603), and the Natural Science Foundation of Guangdong Province (Grant Nos. 2017A030310410, 2017A030310398).
11. Muzes G, Molnar B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. *World J Gastroenterol* (2012) 18(41):5848–61. doi:10.3748/wjg.v18.i41.5848

12. Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. *Pharmacol Res* (2013) 69(1):42–51. doi:10.1016/j.phrs.2012.10.007

13. Walker AW, Lawley TD. Therapeutic modulation of intestinal dysbiosis. *Pharmacol Res* (2013) 69(1):75–86. doi:10.1016/j.phrs.2012.09.008

14. Frank DN, St Amand AL, Feldman RA, Boedecker EC, Harpaz N, Pace NR. Molecular-phylelogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* (2007) 104(34):13780–5. doi:10.1073/pnas.0706625104

15. Wong JM, de Souza R, Kendall CW, Emmann A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol* (2006) 40(3):235–43. doi:10.1097/00004836-200603000-00015

16. D’Souza WN, Douangpanya J, Mu S, Jacek P, Zhang M, Maxwell JR, et al. Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. *PLoS One* (2017) 12(7):e0180190. doi:10.1371/journal.pone.0180190

17. Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab* (2011) 13(5):517–26. doi:10.1016/j.cmet.2011.02.018

18. Mishra T, Kosukosi R, Otani A, Ansary MM, Tongu M, Harashima N, et al. Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8. *Lab Invest* (2013) 93(7):834–43. doi:10.3328/lab.2013.70

19. Celasco G, Moro L, Aiello C, Mangano K, Milasi A, Quattrocieli C, et al. Calcium butyrate: anti-inflammatory effect on experimental colitis in rats and antioxidant properties. *Biomed Rep* (2014) 2(4):559–63. doi:10.3829/br.2014.273

20. Hou Y, Wang L, Yi D, Ding B, Chen X, Wang Q, et al. Dietary supplementation with tributyrin alleviates intestinal injury in piglets challenged with intrarectal administration of acetic acid. *Cell Host Microbe* (2012) 18(41):5848–61. doi:10.1016/j.chom.2015.03.005

21. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, et al. Aggravation of different types of experimental colitis by depletion or dietary short-chain fatty acids. *PLoS One* (2011) 2011:869647.

22. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg MCO.0b013e32834f4598

23. Licciardi PV, Verkeris K, Karagiannis TC. Histone deacetylase inhibition and cell proliferation. *Cell Host Microbe* (2007) 2012.08.033

24. Vinolo MA, Hirabara SM, Curi R. G-protein-coupled receptors as fat sensors. *Curr Opin Clin Nutr Metab Care* (2012) 48(4):612–26. doi:10.1016/j.molcel.2011.02.018

25. Mutoh M, Yachida N, Yamaguchi H, Yanagisawa M, Kimura Y, Sasano H, et al. Calcium butyrate activates GPR43 on intestinal epithelial cells to promote inflammation. *Nature* (2009) 461(7268):25481–9. doi:10.1038/jbc.M301403200

26. Jeffery CJ. Moonlighting proteins.

27. Fredriksson R, Schioth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes.

28. Mani M, Chen C, Amblee V, Liu H, Mathur T, Zwicke G, et al. MoonProt: a novel SCFA receptor, the microbiota, and blood pressure regulation. *Gut Microbes* (2014) 5(2):202–7. doi:10.4161/gmic.27492

29. Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. *J Gastroenterol* (2017) 52(1):1–8. doi:10.1007/s00535-016-1242-9

30. Brown AJ, Goldworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* (2003) 278(13):11312–9. doi:10.1074/jbc.M211609200

31. Le Poul E, Loison C, Strauf S, Springael DY, Lannoy V, Decobègue ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem* (2003) 278(28):25481–9. doi:10.1074/jbc.M211609200

32. Yang et al. GPR43 and Intestinal Inflammation

33. Le Poul E, Loison C, Strauf S, Springael DY, Lannoy V, Decobègue ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem* (2003) 278(28):25481–9. doi:10.1074/jbc.M211609200

34. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFAR2, expressed on leukocytes and activated by short-chain fatty acids. *Biochem Biophys Res Commun* (2003) 303(4):1047–52. doi:10.1016/S0006-291X(03)01088-1

35. Ang Z, Er JZ, Ding JL. The short-chain fatty acid receptor GPR43 is transcriptionally regulated by XBPI in human monocytes. *Sci Rep* (2015) 5:8134. doi:10.1038/srep08134

36. Maslowski KM, Vieira AT, Funaki Y, Ogasawara N, Mizuno M, Iida A, et al. G protein-coupled receptor 43 modulates gut inflammation through cytokine regulation from mononuclear cells. *Inflamm Bowel Dis* (2013) 19(13):2848–56. doi:10.1097/MIB.0b013e3183045444.14860.ea

37. Masui R, Sasaki M, Funaki Y, Ogasawara N, Mizuno M, Iida A, et al. G protein-coupled receptor 43 modulates gut inflammation through cytokine regulation from mononuclear cells. *Inflamm Bowel Dis* (2013) 19(13):2848–56. doi:10.1097/MIB.0b013e3183045444.14860.ea

38. Sina C, Gavrilova O, Forster M, Till A, Derer S, Hildebrand F, et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. *J Immunol* (2009) 183(11):5714–22. doi:10.4049/jimmunol.0900063

39. Kespohl M, Vachharajani N, Luu M, Harb H, Paultz S, Wolf S, et al. The microbial metabolite butyrate induces expression of Thi1-associated factors in CD4(+) T cells. *Front Immunol* (2017) 8:1036. doi:10.3389/fimmu.2017.01036

40. Nathans N. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* (2006) 6(3):173–82. doi:10.1038/nri1785

41. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, et al. Aggravation of different types of experimental colitis by depletion or dietary short-chain fatty acids. *PLoS One* (2011) 2011:869647.

42. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* (2006) 6(3):173–82. doi:10.1038/nri1785

43. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, et al. Aggravation of different types of experimental colitis by depletion or dietary short-chain fatty acids. *PLoS One* (2011) 2011:869647.

44. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* (2006) 6(3):173–82. doi:10.1038/nri1785

45. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, et al. Aggravation of different types of experimental colitis by depletion or dietary short-chain fatty acids. *PLoS One* (2011) 2011:869647.

46. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* (2006) 6(3):173–82. doi:10.1038/nri1785
52. Ren W, Liu G, Yin J, Tan B, Wu G, Bazer FW, et al. Amino-acid transporters in T-cell activation and differentiation. *Cell Death Dis* (2017) 8(3):e2655. doi:10.1038/cddis.2016.222

53. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunology* (2016) 5(4):e73. doi:10.1038/cti.2016.17

54. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. *Inflamm Bowel Dis* (2009) 15(3):341–52. doi:10.1002/ibd.20753

55. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. *Mucosal Immunol* (2015) 8:80–93. doi:10.1038/mi.2014.44

56. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* (2013) 341(6145):569–73. doi:10.1126/science.1241165

57. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. *Int J Med Microbiol* (2008) 298(5–6):463–72. doi:10.1016/j.ijmm.2007.07.016

58. Huda-Faujan N, Abdulamir AS, Fatimah AB, Anas OM, Shuhaimi M, Azid AM, et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. *Open Biochem J* (2010) 4:53–8. doi:10.2174/1874091X01004010053

59. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. *Gastroenterology* (1992) 103(1):51–6. doi:10.1016/0016-5085(92)91094-K

60. Vernia P, Marcheggiano A, Caprilli R, Frieri G, Corrao G, Valpiani D, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. *Aliment Pharmacol Ther* (1995) 9(3):309–13. doi:10.1111/j.1365-2036.1995.tb00386.x

61. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. *German-Austrian SCFA Study Group. Dig Dis Sci* (1996) 41(11):2254–9. doi:10.1007/BF02071409

62. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. *Gut* (1997) 40(4):485–91. doi:10.1136/gut.40.4.485

63. Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. *Eur J Clin Invest* (2003) 33(3):244–8. doi:10.1046/j.1365-2362.2003.01130.x

64. Kim M, Qie Y, Park J, Kim CH. Gut microbial metabolites fuel host antibody responses. *Cell Host Microbe* (2016) 20(2):202–14. doi:10.1016/j.chom.2016.07.001

65. Wu W, Sun M, Chen F, Cao AT, Liu H, Zhao Y, et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to micro-biota which is mediated by GPR43. *Mucosal Immunol* (2017) 10(4):946–56. doi:10.1038/mi.2016.114

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Yang, Chen, Deng, Tan, Deng, Zhu, Yin and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.